Reuters logo
BRIEF-Ipsen and Exelixis announce IRC confirms cabozantinib significantly improved progression-free survival compared to sunitinib
June 19, 2017 / 5:33 PM / 5 months ago

BRIEF-Ipsen and Exelixis announce IRC confirms cabozantinib significantly improved progression-free survival compared to sunitinib

June 19 (Reuters) - IPSEN SA:

* IPSEN SA - IPSEN AND ITS PARTNER EXELIXIS ANNOUNCE INDEPENDENT RADIOLOGY COMMITTEE REVIEW CONFIRMS RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

* E.U. REGULATORY SUBMISSION REMAINS ON TRACK FOR Q3 2017

* IRC CONFIRMS CABOZANTINIB SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL COMPARED TO SUNITINIB Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below